377 related articles for article (PubMed ID: 24311725)
1. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
2. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy.
Wharton GT; Murphy MD; Avant D; Goldsmith JV; Chai G; Rodriguez WJ; Eisenstein EL
Pediatrics; 2014 Aug; 134(2):e512-8. PubMed ID: 25022732
[TBL] [Abstract][Full Text] [Related]
3. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
Mathis LL; Iyasu S
Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
[TBL] [Abstract][Full Text] [Related]
4. Pediatric research: coming of age in the new millennium.
Milne CP
Am J Ther; 1999 Sep; 6(5):263-82. PubMed ID: 11329108
[TBL] [Abstract][Full Text] [Related]
5. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
Roberts R; Rodriguez W; Murphy D; Crescenzi T
JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
[TBL] [Abstract][Full Text] [Related]
6. Stimulation programs for pediatric drug research--do children really benefit?
Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J
Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950
[TBL] [Abstract][Full Text] [Related]
7. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
8. A new history and discussion of 180-day exclusivity.
Korn DE; Lietzan E; Scott SW
Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
[TBL] [Abstract][Full Text] [Related]
9. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
10. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
[TBL] [Abstract][Full Text] [Related]
11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
12. Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.
Sinha MS; Najafzadeh M; Rajasingh EK; Love J; Kesselheim AS
JAMA Intern Med; 2018 Nov; 178(11):1458-1466. PubMed ID: 30264138
[TBL] [Abstract][Full Text] [Related]
13. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
14. Economic return of clinical trials performed under the pediatric exclusivity program.
Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
[TBL] [Abstract][Full Text] [Related]
15. Peer-reviewed publication of clinical trials completed for pediatric exclusivity.
Benjamin DK; Smith PB; Murphy MD; Roberts R; Mathis L; Avant D; Califf RM; Li JS
JAMA; 2006 Sep; 296(10):1266-73. PubMed ID: 16968851
[TBL] [Abstract][Full Text] [Related]
16. Has the FDA Amendments Act of 2007 impaired drug development?
Franson TR
Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
[TBL] [Abstract][Full Text] [Related]
17. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
18. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
[TBL] [Abstract][Full Text] [Related]
19. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
20. Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.
Vernon JA; Shortenhaus SH; Mayer MH; Allen AJ; Golec JH
Paediatr Drugs; 2012 Oct; 14(5):283-94. PubMed ID: 22775493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
